Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion Deciphera Shareholders to Receive $25.60 per Share in Cash Deciphera’s Kinase Inhibitor Expertise and Established Commercialization Platform in Key Markets Will Reinforce ONO...
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem –First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved– –Potential Approval Early Q4 2024–...
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) – Rallybio to Receive Funding for FNAIT Awareness Initiative and Equity Investment from Johnson &...
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer – Arvinas to receive a $150 million upfront...
Recent Comments